(Press-News.org) Night owls have a higher BMI, larger waists, more hidden body fat and are almost 50% more likely to develop type 2 diabetes (T2D) than those who go to bed earlier, new research to be presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), has found.
Lead researcher Dr Jeroen van der Velde, of Leiden University Medical Centre, Leiden, Netherlands, says: “Previous studies have indicated that a late chronotype – preferring to go to bed late and wake up later – is associated with an unhealthy lifestyle. Late chronotypes are more likely to smoke or have an unhealthy diet, for example, and it has been suggested this is why they are higher risk of obesity and metabolic disorders including type 2 diabetes.
“However, we believe that lifestyle cannot fully explain the relationship between a late chronotype and metabolic disorders. In addition, while it is known that a late chronotype is associated with high BMI, it isn’t clear to what extent chronotype affects body fat distribution.”
To find out more, Dr van der Velde and colleagues studied the association between sleep timing, T2D and body fat distribution in more than 5,000 individuals, as part of the Netherlands Epidemiology of Obesity study, an ongoing study into the influence of body fat on disease.
The analysis involved participants (54% female) with a mean age of 56 years and mean BMI of 30 kg/m2.
Participants filled in a questionnaire their typical bed and waking times and from this midpoint of sleep (MPS) was calculated.
The participants were then divided into three groups: early chronotype (the 20% of participants with the earliest MPS), late chronotype (the 20% of participants with the latest MPS) and intermediate chronotype (the remaining 60% of participants).
BMI and waist circumference were measured in all participants. Visceral fat and liver fat were measured in 1,526 participants, using MRI scans and MR spectroscopy, respectively.
The participants were followed-up for a median of 6.6 years, during which 225 were diagnosed with T2D.
The results, which were adjusted for age, sex, education, total body fat and a range of lifestyle factors (physical activity, diet quality, alcohol intake, smoking and sleep quality and duration), showed that compared with an intermediate chronotype, participants with a late chronotype had a 46% higher risk of T2D.
This suggests that the increased risk of T2D in late chronotypes can’t be explained by lifestyle alone.
“We believe that other mechanisms are also at play,” says Dr van der Velde. “A likely explanation is that the circadian rhythm or body clock in late chronotypes is out of sync with the work and social schedules followed by society. This can lead to circadian misalignment, which we know can lead to metabolic disturbances and ultimately type 2 diabetes.”
The team also looked at T2D risk in early chronotypes.
“From the literature, we expected early chronotypes to have a similar risk of developing type 2 diabetes as intermediate chronotypes,” says Dr van der Velde. “Our results showed a slightly higher risk but this was not statistically significant.”
The results also showed that late chronotypes had a 0.7 kg/m2 higher BMI, 1.9 cm larger waist circumference, 7 cm2 more visceral fat and 14% higher liver fat content, compared with those with an intermediate chronotype.
Dr van der Velde concludes: “People with a late chronotype appear to be at greater risk of developing type 2 diabetes compared to those with intermediate chronotype, possibly because of higher body fat including more visceral fat and liver fat.
“The next step is to study if those with a late chronotype improve in metabolic health when they make changes in the timing of their lifestyle habits.
“We are currently involved in the TIMED consortium1, where the complex interplay of the timing of sleep, food intake and physical activity in relation to type 2 diabetes is examined. We previously showed that timing of physical activity is important in relation to insulin resistance.”
Another example would be to alter the timing of meals. “People with a late chronotype are probably more likely to eat until later in the evening,” says Dr van der Velde. “While we did not measure this in our study, there is growing evidence that time-restricted eating, not eating anything after a certain time, such as 6pm, may lead to metabolic benefits.
“Night owls who are concerned about the increased risk of type 2 diabetes might want to try this or, at least, try to refrain from eating late in the evening.
“The evidence isn’t there yet but, in time, we aim to provide specific advice regarding the timing of lifestyle behaviour.”
END
Night owls are more likely to develop type 2 diabetes – and it’s not just because of an unhealthy lifestyle, Dutch study finds
2024-09-09
ELSE PRESS RELEASES FROM THIS DATE:
Air travel may affect insulin pump delivery in people with type 1 diabetes
2024-09-09
Altitude changes during commercial flights may affect the blood glucose levels of people with type 1 diabetes who are treated with insulin pump therapy, according to new research to be presented at this year’s Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).
“We investigated the effect atmospheric pressure changes during flight can have on insulin pumps following concerns that glucose levels may drop below the normal ranges during or immediately after flights,” explained lead author Dr Ka Siu Fan from the Royal Surry County Hospital and University ...
Fruit and oats raise risk of type 1 diabetes but berries provide protection, research suggests
2024-09-09
New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), shows that eating fruit, oats and rye in childhood is associated with a higher risk of developing type 1 diabetes (T1D). Eating berries, however, is linked to lower odds of developing the condition.
T1D is an autoimmune condition in which the immune system attacks and destroys the insulin-producing islet cells in the pancreas. This prevents the body from producing enough of the hormone insulin to properly regulate blood sugar levels.
What triggers the immune system’s attack is unknown but is thought to involve a combination ...
Patients receiving steroids are more than twice as likely to develop diabetes, UK study has found
2024-09-09
Patients who are being treated with systemic glucocorticoids are more than twice as likely to develop diabetes as those not receiving the treatment, the Annual Meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear.
Glucocorticoids (sometimes known as steroids) fight inflammation and are used to treat a wide range of inflammatory and autoimmune conditions, including asthma, rheumatoid arthritis, cancers and other medical problems.
While they can be very effective in decreasing inflammation, glucocorticoids have many adverse effects including ...
Perioperative nivolumab may provide meaningful improvement in event-free survival compared to only neoadjuvant nivolumab plus chemotherapy for resectable NSCLC
2024-09-08
(San Diego, Calif--September 8, 2024, 10:05 a.m. PCT) – New data from landmark analysis presented today report a decreased risk of disease recurrence or death in patients with resectable NSCLC who received adjuvant nivolumab following neoadjuvant nivolumab plus chemotherapy and surgery compared to those who received only neoadjuvant nivolumab plus chemotherapy.
The data was reported at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
This is the first analysis of individual patient-level data from two phase 3 trials, CheckMate 77T and CheckMate 816, to examine which patients may derive benefit from ...
PanCan nodule management protocol more effective than LungRADSv1.1 method
2024-09-08
(San Diego, Calif.--September 8, 2024, 10:05 a.m. PCT) – New data presented today reveals that the PanCan nodule management protocol demonstrates superior performance in triaging lung cancer screening participants compared to the LungRADSv1.1 approach. Specifically, PanCan showed improved risk stratification and reduced the number of low-dose computed tomography(CT) scans required.
The research was reported by Dr. Annette McWilliams, Fiona Stanley Hospital, Australia at the International Association for the Study of Lung Cancer 2024 World Conference on Lung Cancer.
The ...
Normalized membrane ratio of TROP2 by quantitative continuous scoring predictive of clinical outcomes in TROPION-Lung 01
2024-09-08
(San Diego, Calif.--September 8, 2024, 10:05 a.m. PCT) – New data presented today demonstrate that TROP2 expression as measured by quantitative continuous scoring (QCS), a computational pathology approach, is a promising predictor of clinical outcomes in patients with advanced or metastatic non-small cell lung cancer (NSCLC) treated with the TROP2 antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd). The data showed that patients with TROP2 positivity, as determined by QCS, experienced improved efficacy with Dato-DXd compared to patients receiving docetaxel ...
Ivonescimab outperforms pembrolizumab in phase 3 study for first-line treatment of PD-L1-positive advanced NSCLC in HARMONi-2 study
2024-09-08
(San Diego, Calif--September 8, 2024, 8:30 a.m.) — Data from a Phase 3 study revealed that ivonescimab demonstrates a statistically significant and clinically meaningful improvement in progression-free survival compared to pembrolizumab for patients with PD-L1-positive advanced non-small cell lung cancer. The results were presented today at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer.
The HARMONi-2 study randomized 398 patients ...
NeoCOAST-2 Data shows combination of Durvalumab with novel agents increases pathological responses in resectable NSCLC -- Data builds on AEGEAN study research
2024-09-08
(San Diego, Calif. September 8, 2024 10:05 a.m. PCT) – Phase 2 results from the NeoCOAST-2 study demonstrated that the combination of durvalumab with Dato-DXd yielded the highest pathological complete response rates among the tested regimens.
The data was presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer by Dr. Tina Cascone, from The University of Texas MD Anderson Cancer Center in Houston.
“The findings highlight the potential of combining durvalumab with novel anticancer agents to build on what we have learned in the perioperative immunotherapy arena for patients with ...
Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence
2024-09-08
People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
For the study, researchers compared health outcomes among 147 participants in the CheckMate 816 study — in which patients received three cycles of the immunotherapy nivolumab plus chemotherapy before surgery (neoadjuvant) — with results of 139 participants in the CheckMate 77T trial, in which patients received up to four cycles of nivolumab plus chemotherapy ...
Young vapers perform worse in exercise testing
2024-09-08
Young people who vape perform worse than non-vapers in tests designed to measure their capacity for exercise, according to a study presented at the European Respiratory Society (ERS) Congress in Vienna, Austria [1]. The research also showed that the performance of young vapers was similar to that of young smokers.
The study adds to growing evidence that long-term use of vaping is harmful and challenges the idea that vaping could be a healthier alternative to smoking.
The research was presented by Dr Azmy Faisal, senior lecturer in cardiorespiratory physiology in the department of sport and exercise sciences at Manchester Metropolitan ...